Cover Image
市場調查報告書

全球鼻腔給藥市場與開發平台分析

Global Intranasal Drug Delivery Market & Pipeline Insight

出版商 KuicK Research 商品編碼 311720
出版日期 內容資訊 英文 566 Pages
商品交期: 最快1-2個工作天內
價格
Back to Top
全球鼻腔給藥市場與開發平台分析 Global Intranasal Drug Delivery Market & Pipeline Insight
出版日期: 2014年09月01日 內容資訊: 英文 566 Pages
簡介

在鼻子噴劑或吸入器等藥劑來自行服藥的患者增加下,預測這些鼻腔給藥產品的市場在近未來將會穩定成長。此外新企業的參與也將刺激這個需求的擴大。慢性疾病的發病件數今後預測也將增加,這些情況應該也將是推動鼻腔給藥技術市場的主要要素。

本報告提供鼻腔給藥市場相關調查,為您彙整鼻腔給藥的機制與投與形態,目的,市場規模的變化與預測,適應症·階段·企業·各國開發平台藥物簡介,已上市藥物簡介,主要製藥公司配合措施等資料。

第1章 簡介:鼻腔給藥

第2章 鼻腔給藥的機制

  • 經鼻吸收的機制
  • 鼻用藥物的類型
    • 液體製劑
    • 加壓MDI
    • 粉末用設備
    • 鼻用凝膠

第3章 鼻腔給藥的需求

第4章 鼻腔給藥的用途

  • 非胜肽醫藥品的給藥
  • 胜肽醫藥品的給藥
  • 經鼻腔到腦部的藥物遞輸
  • 經鼻腔的疫苗給藥
  • 診斷藥的給藥

第5章 鼻腔給藥市場概要

  • 目前市場方案
  • 經鼻藥物的開發平台概要

第6章 市場動態

  • 有利的市場參數
  • 藥物遞輸的課題

第7章 未來展望

  • 未來方案
  • 給藥設備的演進

第8章 經鼻藥物臨床平台:適應症·階段·企業·各國

  • 研究
  • 前臨床
  • 臨床
  • 階段I
  • 階段I/II
  • 階段II
  • 階段II/III
  • 階段III
  • 登記前
  • 登記完畢

第9章 已上市經鼻藥物:適應症·企業·各國

第10章 開發延期·中止的藥物:適應症·階段·企業·各國

  • 無進展報告
  • 中止
  • 市場撤退
  • 延期

第11章 競爭環境

  • Aegis Therapeutics
  • Archimedes Pharma
  • GlaxoSmithKline
  • MEDA AB
  • MedImmune
  • Merck
  • NanoBio Corporation
  • Novartis
  • OptiNose
  • Pherin Pharmaceuticals

圖表

目錄

Intranasal drug delivery has evolved in the recent years as a significant method of delivering drugs through the nasal route. This method has been identified to have all the potential to achieve significant milestones in the pharmaceutical industry, as it is largely driven by its capability to cure local infections and chronic allergies. The human nose, which has a unique vascular structure, makes it specifically accessible for delivering small molecule drugs and biologics. By taking advantage of the conducive healthcare trends and changing demography, the intranasal drug delivery route is likely to capture the popularity of other leading methods of drug delivery such as oral and parenteral.

The use of nasal sprays and inhalers has had a great impact in improving the drug administration experience, enhancing compliance rates, and ensuring safety. These systems have emerged as a segment with huge potential for the future and are playing an increasingly prominent role in a range of competitive intranasal devices markets. The growth and competitiveness of the intranasal drugs and devices market has led to the extensive development and innovation of new and nth-generation devices which have the capacity to overcome the limitations of the previous drug delivery technologies.

With an increasing number of patients preferring to use self-administering devices like sprays and inhalers to avoid the pain, the market for these products is likely to grow at a substantial rate in the near future. This increasing demand is also having a great impact in terms of attracting new companies into the market. The future years are expected to witness a steady increase in chronic diseases, if not a rapid increase and this is also a major driver of intranasal drug delivery technologies.

The intranasal drug delivery market is likely to witness more developments in formulation techniques, like improvised micro-encapsulation techniques, more use of muco adhesive and surfactant agents and nanotechnology. This would in turn lead to an increased number of new chemical entities which could possibly be considered as the active ingredients for future intranasal drug products. Similarly, it is also expected that modern approaches to vaccination would be increasingly used which could also generate a wide range of new prophylactic and therapeutic products which would be appropriate for delivery through the nasal route.

“Global Intranasal Drug Delivery Market & Pipeline Insight” Report Highlights:

  • Intranasal Drug Delivery Market Overview
  • Mechanism & Application Intranasal Drug Delivery
  • Nasal Drug Delivery System: Powder, Gels, Liquid & Pressurized MDI
  • Intranasal Drug Clinical Pipeline Insight by Indication, Phase, Company & Country
  • Intranasal Drug Clinical Pipeline: 177 Drugs
  • Majority Drugs in Preclinical Phase: 65
  • Market Intranasal Drugs: 34

Table of Contents

1. Introduction to Intranasal Drug Delivery

2. Intranasal Drug Delivery Mechanism

  • 2.1. Mechanism of Nasal Absorption
  • 2.2. Types of Nasal Drug Delivery System Dosages
    • 2.2.1. Liquid Nasal Formulations
    • 2.2.2. Pressurized MDI
    • 2.2.3. Powder Devices
    • 2.2.4. Nasal Gels

3. Need for Intranasal Drug Delivery

4. Applications of Intranasal Drug Delivery

  • 4.1. Delivery of Non Peptide Pharmaceuticals
  • 4.2. Delivery of Peptide Based Pharmaceuticals
  • 4.3. Delivery of Drugs to Brain through Nasal Cavity
  • 4.4. Delivery of Vaccines through Nasal Route
  • 4.5. Delivery of Diagnostic Drugs

5. Intranasal Drug Delivery Market Overview

  • 5.1. Current Market Scenario
  • 5.2. Intranasal Drug Clinical Pipeline Overview

6. Intranasal Drug Delivery Market Dynamics

  • 6.1. Favorable Market Parameters
  • 6.2. Challenges in Drug Delivery

7. Intranasal Drug Delivery Market Future Outlook

  • 7.1. Future Scenario
  • 7.2. Advances in Delivery Devices

8. Intranasal Drug Clinical Pipeline by Indication, Phase, Company & Country

  • 8.1. Research
  • 8.2. Preclinical
  • 8.3. Clinical
  • 8.4. Phase-I
  • 8.5. Phase-I/II
  • 8.6. Phase-II
  • 8.7. Phase-II/III
  • 8.8. Phase-III
  • 8.9. Preregistration
  • 8.10. Registered

9. Marketed Intranasal Drugs by Indication, Company & Country

10. Suspended & Discontinued Intranasal Drugs in Clinical Pipeline by Indication, Phase, Company & Country

  • 10.1. No Development Reported
  • 10.2. Discontinued
  • 10.3. Market Withdrawal
  • 10.4. Suspended

11. Competitive Landscape

  • 11.1. Aegis Therapeutics
  • 11.2. Archimedes Pharma
  • 11.3. GlaxoSmithKline
  • 11.4. MEDA AB
  • 11.5. MedImmune
  • 11.6. Merck
  • 11.7. NanoBio Corporation
  • 11.8. Novartis
  • 11.9. OptiNose
  • 11.10. Pherin Pharmaceuticals

List of Figures

  • Figure 1-1: Intranasal Drug Delivery Formulations
  • Figure 2-1: Intranasal Drug Delivery Mechanism
  • Figure 2-2: Nasal Drug Delivery System Dosages Forms
  • Figure 5-1: Composition of Drug Delivery Market
  • Figure 5-2: Global Intranasal Drug Delivery Market (US$ Billion), 2013-2018
  • Figure 5-3: Intranasal Drug Delivery Therapeutic Applications
  • Figure 5-4: Regional Break-up of Intranasal Drug Delivery Market
  • Figure 5-5: Intranasal Drug Clinical Pipeline by Phase (%), 2014
  • Figure 5-6: Intranasal Drug Clinical Pipeline by Phase (Number), 2014
  • Figure 5-7: No Development Reported in Intranasal Drug by Phase (%), 2014
  • Figure 5-8: No Development Reported in Intranasal Drug by Phase (Number), 2014
  • Figure 5-9: Discontinued Intranasal Drug in Pipeline by Phase (%), 2014
  • Figure 5-10: Discontinued Intranasal Drug in Pipeline by Phase (Number), 2014
  • Figure 5-11: Suspended Intranasal Drug in Pipeline by Phase (%), 2014
  • Figure 5-12: Suspended Intranasal Drug in Pipeline by Phase (Number), 2014
  • Figure 11-1: NanoBio Clinical Pipeline
  • Figure 11-2: Pherin Pharmaceuticals
Back to Top